Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with

K Sonouchi1, T A Hamilton, C S Tannenbaum

  • 1Department of Immunology, Cleveland Clinic Foundation, OH 46195.

Insights

Cytokine therapy with interferon-alpha and interleukin-2 increases chemokine gene expression in murine renal cell carcinoma (RENCA). This correlates with increased inflammatory leukocyte infiltration, suggesting RENCA cells may drive this response.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Cytokine therapy is investigated for cancer treatment.
  • Interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) are key immunomodulatory cytokines.
  • Chemokines play a role in leukocyte recruitment to tumors.

Purpose of the Study:

  • To examine chemokine mRNA expression in murine renal cell carcinoma (RENCA) after IFN-alpha/IL-2 treatment.
  • To correlate chemokine expression with inflammatory leukocyte infiltration.
  • To investigate the source of chemokine expression in the tumor microenvironment.

Main Methods:

  • Semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
  • Analysis of murine RENCA tumors from treated and control mice.
  • In vitro stimulation of cultured RENCA cells with cytokines.

Main Results:

  • IFN-alpha/IL-2 treatment significantly elevated mRNA levels for chemokines KC, JE, and IP-10 in RENCA tumors.
  • Tumor necrosis factor-alpha (TNF-alpha) mRNA also increased in treated tumors.
  • Increased expression of Mac-1+ leukocytes correlated with elevated chemokine and TNF-alpha mRNA.

Conclusions:

  • RENCA cells can express chemokine mRNAs in response to IFN-alpha, IFN-gamma, and IL-2 in vitro.
  • Cytokine therapy may induce chemokine expression within the tumor bed.
  • TNF-alpha may be expressed by infiltrating monocytes rather than tumor cells.

Related Concept Videos